568 related articles for article (PubMed ID: 32404247)
1. EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
Jareemit N; Horowitz NS; Goldstein DP; Berkowitz RS; Elias KM
Gynecol Oncol; 2020 Jul; 158(1):99-104. PubMed ID: 32404247
[TBL] [Abstract][Full Text] [Related]
2. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
3. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy.
Escobar PF; Lurain JR; Singh DK; Bozorgi K; Fishman DA
Gynecol Oncol; 2003 Dec; 91(3):552-7. PubMed ID: 14675675
[TBL] [Abstract][Full Text] [Related]
4. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM
Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.
Deng L; Zhang J; Wu T; Lawrie TA
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD005196. PubMed ID: 23440800
[TBL] [Abstract][Full Text] [Related]
6. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
7. M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first-line treatment of high-risk gestational trophoblastic neoplasia.
Singh K; Gillett S; Ireson J; Hills A; Tidy JA; Coleman RE; Hancock BW; Winter MC
Int J Cancer; 2021 May; 148(9):2335-2344. PubMed ID: 33210289
[TBL] [Abstract][Full Text] [Related]
8. [Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia].
Xue W; Yang JJ; Zhao J; Ren T; Feng FZ; Wan XR; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):377-383. PubMed ID: 29961279
[No Abstract] [Full Text] [Related]
9. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
10. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
11. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
12. Changes in the management of high-risk gestational trophoblastic neoplasia in the National Trophoblastic Disease Center of Hungary.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Berkowitz RS
J Reprod Med; 2014; 59(5-6):227-34. PubMed ID: 24937962
[TBL] [Abstract][Full Text] [Related]
13. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia.
Lurain JR; Schink JC
J Reprod Med; 2012; 57(5-6):219-24. PubMed ID: 22696816
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?
Essel KG; Bruegl A; Gershenson DM; Ramondetta LM; Naumann RW; Brown J
Gynecol Oncol; 2017 Jul; 146(1):74-80. PubMed ID: 28473205
[TBL] [Abstract][Full Text] [Related]
15. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
17. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
[TBL] [Abstract][Full Text] [Related]
18. Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
Yang J; Xiang Y; Wan X; Feng F; Ren T
Gynecol Oncol; 2016 Oct; 143(1):68-72. PubMed ID: 27426306
[TBL] [Abstract][Full Text] [Related]
19. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Cagayan MS
J Reprod Med; 2012; 57(5-6):231-6. PubMed ID: 22696818
[TBL] [Abstract][Full Text] [Related]
20. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
